Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation - PubMed (original) (raw)
. 1986 Apr 1;136(7):2398-407.
- PMID: 2869085
Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation
R H Buckley et al. J Immunol. 1986.
Abstract
Recent advances in the prevention of graft-vs-host disease (GVHD) have allowed the use of haploidentical bone marrow cells for correction of lethal genetic defects of the immune system. Sequential analyses of blood lymphocyte phenotypes and functions were done before and after transplantation of haploidentical marrow stem cells into 17 infants with severe primary T cell deficiencies. The marrow was depleted of post-thymic T cells and most other mature marrow cells by soy lectin agglutination and sheep erythrocyte rosetting. The studies were performed to define the time course and extent of appearance of immune function, and to identify factors leading to resistance to engraftment. No pretransplant immunosuppression was used. T cell function was detected between 34 and 287 days after transplantation, but a sharp rise usually occurred between 84 and 115 days, and normal function was reached between 113 and 210 days. Fifteen of the patients are alive from 6 to 41 mo post-transplantation, 12 have improved or have normal T lymphocyte function, and nine have proven T cell chimerism. Increased immunoglobulins of several isotypes have been noted in 11 patients and specific antibodies in seven patients, although B cell chimerism has been detected in only one patient. B cell function required 2 to 2.5 yr for normalization. No GVHD occurred in 14 patients, and the other three had only transient mild skin rashes. Two patients died of viral infections. Failure to engraft was correlated with some pre-transplant lymphocyte responses to mitogens and allogeneic cells (three cases), but not with the presence of pre-transplant natural killer cell function (five cases) nor with the presence of purine salvage pathway enzyme deficiencies (four cases). The latter, however, was associated with poor lymphoid function in two patients. These studies indicate that the thymic microenvironment of most infants with severe combined immunodeficiency disease is capable of differentiating donor stem cells to mature and functioning T lymphocytes which can cooperate with apparently normal host B cells for antibody production.
Similar articles
- Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.
Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, Myers LA, Ward FE. Buckley RH, et al. N Engl J Med. 1999 Feb 18;340(7):508-16. doi: 10.1056/NEJM199902183400703. N Engl J Med. 1999. PMID: 10021471 Clinical Trial. - Bone marrow transplantation for the treatment of immune deficiency states.
Lenarsky C, Parkman R. Lenarsky C, et al. Bone Marrow Transplant. 1990 Dec;6(6):361-9. Bone Marrow Transplant. 1990. PMID: 1965792 Review. - Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency.
Buckley RH, Schiff SE, Schiff RI, Roberts JL, Markert ML, Peters W, Williams LW, Ward FE. Buckley RH, et al. Semin Hematol. 1993 Oct;30(4 Suppl 4):92-101; discussion 102-4. Semin Hematol. 1993. PMID: 7905667 Review.
Cited by
- Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies.
Serana F, Chiarini M, Zanotti C, Sottini A, Bertoli D, Bosio A, Caimi L, Imberti L. Serana F, et al. J Transl Med. 2013 May 9;11:119. doi: 10.1186/1479-5876-11-119. J Transl Med. 2013. PMID: 23656963 Free PMC article. Review. - Carrier detection in X-linked severe combined immunodeficiency based on patterns of X chromosome inactivation.
Puck JM, Nussbaum RL, Conley ME. Puck JM, et al. J Clin Invest. 1987 May;79(5):1395-400. doi: 10.1172/JCI112967. J Clin Invest. 1987. PMID: 2883199 Free PMC article. - Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes.
Buckley RH. Buckley RH. Immunol Res. 2011 Apr;49(1-3):25-43. doi: 10.1007/s12026-010-8191-9. Immunol Res. 2011. PMID: 21116871 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical